We chose to prioritize studies in Ewing Sarcoma30, acute myeloid leukemia (AML)26, and multiple myeloma (MM)24 because these lineages have been evaluated with previous generations of USP7 inhibitors. The gene discussed is USP7; the disease is acute myeloid leukemia.